Michael Thomas Henderson Sells 15,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $59.22, for a total transaction of $888,300.00. Following the transaction, the chief executive officer now directly owns 1,339,487 shares in the company, valued at approximately $79,324,420.14. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, October 2nd, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $56.23, for a total transaction of $2,249,200.00.
• On Wednesday, September 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $47.62, for a total value of $1,904,800.00.

Apogee Therapeutics Stock Performance

APGE stock opened at $61.12 on Friday. The firm has a 50 day moving average price of $54.25 and a 200-day moving average price of $48.79. Apogee Therapeutics, Inc. has a 52-week low of $14.19 and a 52-week high of $72.29. The firm has a market capitalization of $2.75 billion, a price-to-earnings ratio of -29.53 and a beta of 2.93.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.60) earnings per share for the quarter, meeting the consensus estimate of ($0.60). As a group, sell-side analysts forecast that Apogee Therapeutics, Inc. will post -2.57 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an “outperform” rating and issued a $87.00 price objective on shares of Apogee Therapeutics in a report on Friday, October 25th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $78.50.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Apogee Therapeutics by 60.7% in the 1st quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company’s stock worth $124,173,000 after buying an additional 705,795 shares in the last quarter. ProShare Advisors LLC bought a new position in shares of Apogee Therapeutics during the 1st quarter valued at $667,000. Point72 DIFC Ltd purchased a new position in shares of Apogee Therapeutics in the 2nd quarter worth $660,000. XTX Topco Ltd bought a new stake in shares of Apogee Therapeutics during the 2nd quarter valued at about $706,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Apogee Therapeutics by 56.8% in the 2nd quarter. Victory Capital Management Inc. now owns 156,266 shares of the company’s stock worth $6,149,000 after purchasing an additional 56,607 shares during the period. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.